Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
Articolo
Data di Pubblicazione:
2016
Citazione:
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer / A. Amatu, L. Barault, C. Moutinho, A. Cassingena, K. Bencardino, S. Ghezzi, L. Palmeri, E. Bonazzina, F. Tosi, R. Ricotta, T. Cipani, P. Crivori, R. Gatto, G. Chirico, G. Marrapese, M. Truini, A. Bardelli, M. Esteller, F. Di Nicolantonio, A. Sartore Bianchi, S. Siena. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 27:6(2016 Jun), pp. 1062-1067. [10.1093/annonc/mdw071]
Abstract:
Background: Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylation. We conducted a phase II study of TMZ enriched by MGMT hypermethylation in archival tumor (AT), exploring dynamic of this biomarker in baseline tumor (BT) biopsy and plasma (liquid biopsy).
We screened 150 mCRC patients for MGMT hypermethylation with methylation-specific PCR on AT from FFPE specimens. Eligible patients (n = 29) underwent BT biopsy and then received TMZ 200 mg/m(2) days 1-5 q28 until progression. A Fleming single-stage design was used to determine whether progression-free survival (PFS) rate at 12 weeks would be a parts per thousand yen35% [H0 a parts per thousand currency sign 15%, type I error = 0.059 (one-sided), power = 0.849]. Exploratory analyses included comparison between MGMT hypermethylation in AT and BT, and MGMT methylation testing by MethylBEAMing in solid (AT, BT) and LB with regard to tumor response.
The PFS rate at 12 weeks was 10.3% [90% confidence interval (CI) 2.9-24.6]. Objective response rate was 3.4% (90% CI 0.2-15.3), disease control rate 48.3% (90% CI 32.0-64.8), median OS 6.2 months (95% CI 3.8-7.6), and median PFS 2.6 months (95% CI 1.4-2.7). We observed the absence of MGMT hypermethylation in BT in 62.7% of tumors.
Treatment of mCRC with TMZ driven by MGMT promoter hypermethylation in AT samples did not provide meaningful PFS rate at 12 weeks. This biomarker changed from AT to BT, indicating that testing BT biopsy or plasma is needed for refined target selection.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
MGMT; MethylBEAMing; colorectal cancer; liquid biopsy; temozolomide
Elenco autori:
A. Amatu, L. Barault, C. Moutinho, A. Cassingena, K. Bencardino, S. Ghezzi, L. Palmeri, E. Bonazzina, F. Tosi, R. Ricotta, T. Cipani, P. Crivori, R. Gatto, G. Chirico, G. Marrapese, M. Truini, A. Bardelli, M. Esteller, F. Di Nicolantonio, A. SARTORE BIANCHI, S. Siena
Link alla scheda completa: